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Marine molluscs from the family Muricidae are the source of a homeopathic remedy Murex, which is used to treat a range
of conditions, including cancer. The aim of this study was to evaluate the in vitro bioactivity of egg mass extracts of the
Australian muricid Dicathais orbita,i nc o m p a r i s o nt ot h eMurex remedy, against human carcinoma and lymphoma cells. Liquid
chromatography coupled with mass spectrometry (LC-MS) was used to characterize the chemical composition of the extracts and
homeopathic remedy, focusing on biologically active brominated indoles. The MTS (tetrazolium salt) colorimetric assay was used
to determine eﬀects on cell viability, while necrosis and apoptosis induction were investigated using ﬂow cytometry (propidium
iodide and Annexin-V staining, resp.). Cells were treated with varying concentrations (1–0.01mg/mL) of crude and semi-puriﬁed
extracts or preparations (dilute 1M and concentrated 4mg/mL) from the Murex remedy (4h). The Murex remedy showed little
biological activity against the majority of cell lines tested. In contrast, the D. orbita egg extracts signiﬁcantly decreased cell viability
in the majority of carcinoma cell lines. Flow cytometry revealed these extracts induce necrosis in HT29 colorectal cancer cells,
whereas apoptosis was induced in Jurkat cells. These ﬁndings highlight the biomedical potential of Muricidae extracts in the
development of a natural therapy for the treatment of neoplastic tumors and lymphomas.
1.Introduction
Many marine secondary metabolites possess biological
activities with implications for application as antibiotic,
antiparasitic, antiviral and anticancer agents [1–4]. Marine
molluscs are the source of at least four structurally distinct
anticancer agents, which are currently in phase II and
III clinical trials [5, 6]. The Muricidae (Neogastropoda:
Mollusca) are a cosmopolitan family of predatory marine
gastropods that are historically known for the production
of the ancient dye Tyrian purple (Figure 1). The main dye
pigment, 6,6 -dibromoindigotin (Figure 1(a)) was the ﬁrst
marine natural product reported in the literature and has
attracted substantial scientiﬁc interest [7–11]. Tyrian purple
is generated from the secretions of the hypobranchial glands
of these molluscs, after a series of enzymatic, oxidative
and photochemical reactions [9, 11] from a choline ester
precursor salt of tyrindoxyl sulphate [9, Figure 1(b)]. Tyrian
Purple and its intermediate brominated indole precursors
(Figures 1(c)–1(e)) are also found in muricid egg masses
[8, 11–13], where they are thought to chemically defend the
developing larvae against microbial infection. Preliminary
studies on egg mass extracts suggest these intermediate
precursors possess anticancer activity [11, 14], in addition
to the previously described antibacterial activities [8]. These
unique bioactive secondary metabolites are in the chemical
class of indole alkaloids from which 60% of all medicines are
derived [3].
The brominated intermediate precursor 6-bromo-2-
methylthioindolin-3-one (tyrindoleninone, Figure 1(c)) has
been identiﬁed as a useful anticancer drug lead with
apparent speciﬁcity toward lymphoma cells (LC50 4μM)
compared with freshly isolated, human mononuclear cells
(LC50 195μM) [14]. However, synthesis of this substance has
been problematic due to the instability and rapid oxidation
of the precursors and ﬁnal product. Nevertheless, a number
of related substituted isatin derivatives has been synthesized
and tested for anticancer activity against a range of human
cancer cell lines [14]. The synthesized isatins include 6-
bromoisatin (Figure 1(f)), a natural oxidative by-product of
Tyrian purple synthesis, which is also found in Muricidae
egg masses [8, 12]. Bromination was found to increase the2 Evidence-Based Complementary and Alternative Medicine
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Figure1:TheAustralianmuricidDicathaisorbitapicturedwithfreshlylaideggcapsules,whicharethesourceofbiologicallyactivesecondary
metabolites. (a) 6,6 -Dibromoindigotin; (b) tyrindoxyl sulphate salt, where X = choline esters; (c) tyrindoleninone; (d) tyrindoleninone; (e)
tyriverdin; (f) 6-bromoisatin and (g) 6,6 -dibromoindirubin.
anticancer activity of these isatins and greater selectivity was
identiﬁed toward leukemia and lymphoma cells over breast,
prostate and colorectal carcinoma cell lines [14].
Dye secretion [10] and extracts from the hypobranchial
[9] and reproductive glands of male muricids [15]h a v e
also been shown to contain the structural isomer of Tyr-
ian purple, 6,6 -dibromoindirubin (Figure 1(g)). Bioassay-
guided fractionation of hypobranchial gland secretions have
identiﬁed this isomer as a potent protein kinase inhibitor
[16, 17]. By selectively targeting glycogen synthase kinase-
3 (GSK-3), these indirubin compounds eﬀectively inhibit
cell proliferation [16, 17]. Indirubin derivatives have also
been shown to inhibit Stat3 signaling, inducing apoptosis
in human breast and prostate cancer cells [18]. They
also suppress tumor necrosis factor (TNF)-induced NF-
κB activation in human leukemia and lung adenocarci-
noma cells [19] and signiﬁcantly block proliferation in
lung carcinoma, stomach carcinoma and ﬁbrosarcoma cell
lines [20]. Furthermore, 5-methyl-indirubin displays anti-
tumor activity in lung, renal and prostate in vivo models
for human cancer [21]. Notably, indirubin has also been
identiﬁed as the active ingredient in the traditional Chinese
herbal medicine Danggui Luhui Wan used to treat leukemia
[22].
The homeopathic remedy Murex (purpurea) (hereinafter
referred to as “the Murex remedy”) is also derived from
dye secretions of the Muricidae and has been in use
since the 1800s [23]. The Murex remedy is listed on the
Homeopathic Material Medica for use against a range of
“Women’s problems” including uterine and breast cancer
[24, 25]. In most cases there is little scientiﬁc data available
to support the biological activity of homeopathic remedies
and few have been tested for safety and eﬀectiveness using
rigorous methodologies [26, 27]. Nevertheless, some home-
opathic drugs have recently been tested and shown to have
anti-cancer eﬀects (e.g., [28] and references therein). The
apparent biological activity of organic extracts derived from
the Muricidae (see [8, 11, 16, 29]; Figure 1) suggests that
there may also be some chemical basis to the homeopathic
application of the Murex remedy.
Here we investigate the compounds present in the
Murex remedy and compare them to brominated secondary
metabolites identiﬁed in crude extracts obtained from the
egg masses of Dicathais orbita, a common species of Muri-
cidae located along the temperate coasts of Australia and
New Zealand [30]. A semi-puriﬁed extract was also prepared
from the crude egg mass to concentrate Tyrian purple
precursors, in particular tyrindoleninone (Figure 1(c)). The
anti-proliferative and cytotoxic eﬀects of crude and semi-
puriﬁed egg extracts, as well as the Murex remedy were
compared on a range of human carcinoma, lymphoma and
normal mononuclear cells.Evidence-Based Complementary and Alternative Medicine 3
2. Methods
2.1. Collection of Egg Masses and Preparation of Solvent
Extracts. The egg masses of D. orbita were collected from
coastal intertidal reefs along the Fleurieau Peninsula, South
Australia and from a breeding population held in a recircu-
lating marine aquarium system at Flinders University. A total
of 70 g of egg capsules were collected, wrapped in aluminum
f o i la n ds t o r e da t−70
◦C.
Egg capsules were sliced open in minimum light and
during the extraction procedure, all glassware was covered
in alfoil to exclude light. Organic extracts were prepared
by soaking in 100mL (per 10g eggs) AR grade chloroform
and methanol (1:1, v/v, Selby-Biolab, Pronalys, Melbourne,
Australia) under agitation at 4◦C for 2h, followed by
overnight soaking in fresh solvent then a ﬁnal 2h extraction.
The extracts were then combined, ﬁltered and distilled water
(50mL) added, to enable separation of the chloroform layer,
which was then dried in a rotary evaporator under reduced
pressure with water pump vacuum (337Hg) at 40
◦C. This
extraction procedure enables concentration of the bioactive
indole precursor, tyrindoleninone, in the chloroform layer
[8], and although some tyrindoxyl sulphate salt may be
discarded in the polar layer, preliminary bioassays indicate
the polar extract has relatively limited anticancer activity
(unpublished data). Extracts were transferred to amber vials
in approximately 1mL of 100% DCM, dried under N2 gas
a n ds t o r e di na m b e rv i a l sa t−20
◦C to prevent degradation.
In order to concentrate tyrindoleninone, the crude egg
extracts (1g) were semi-puriﬁed using ﬂash silica chro-
matography pressurized with nitrogen gas, as previously
described[8].Theextractwaspassedthroughasilicacolumn
(40g, 230–400 silica mesh, Merck) using high performance-
liquid chromatography (HPLC) grade dichloromethane
(DCM, Sigma-Aldrich, Chromasolv, Sydney, Australia) as
theelutionsolvent.Fractionswerecollectedfromthecolumn
by visual monitoring of the colored compounds, with the
bright orange fraction containing the previously identiﬁed
tyrindoleninone [8, 31]. Semi-puriﬁed fractions were dried
a n ds t o r e da so u t l i n e da b o v e .
2.2. The Murex Remedy. The homeopathic remedy Murex
Purpurea (1M) was purchased from Washington Homeo-
pathic Products (Berkeley Springs, WV, USA). This diluted
tincture is supplied in 20% EtOH and water. To concentrate
the remedy, 60mL was dried in a rotary evaporator with
pump vacuum (72Hg) at 40
◦C. The evaporated remedy was
then dissolved in DCM, transferred to an amber vial and
stored at −20
◦C.
2.3. Chemical Analysis. A l le x t r a c t sa n dt h ec o n c e n t r a t e d
Murex remedy were analyzed by HPLC (Waters Alliance)
coupled to a mass spectrometer (MS, Micromass Quatro
micro) according to Westley and Benkendorﬀ [15]. Parallel
UV/Vis diode-array detection (DAD) was used at 300nm
and600nmandcompoundsenteredintothemassspectrom-
eterwithelectrosprayionization(ESI).MajorionsinESI-MS
were obtained at the apex of HPLC peaks and compounds
were identiﬁed by the retention time and characteristic mass
ion clusters for Br79 Br81 [15]. Relative proportions of each
compound were calculated from integrated absorption data
at 300nm using MassLynx 4.0 software.
2.4. Cell Culture. Five human cancer cell lines (Caco-2,
colon carcinoma; HT29, colon carcinoma; MCF-7, breast
carcinoma; Jurkat, T cell lymphoma and U937, histio-
cytic lymphoma) and an untransformed rat small intestine
epithelial cell line (IEC-6) were maintained at 37
◦Ci n
a5 %C O 2 humidiﬁed atmosphere. HT29, MCF-7, Jurkat
and U937 cells were maintained in RPMI-1640 medium
(Sigma) supplemented with 10% fetal bovine serum (FBS,
JRC Biosciences, Lenexa, KS, USA), Penicillin/Streptomycin
(Gibco, Invitrogen Corporation, Bethesda, MD, USA) and
200nM L-glutamine (Sigma). Caco-2 and IEC-6 cells
were maintained in Dulbecco’s Modiﬁed Eagle’s Medium
(DMEM, Sigma) supplemented with 20% and 10% FBS,
respectively, Penicillin/Streptomycin (Gibco) and 200nM L-
glutamine (Sigma). Human mononuclear cells (MNC) were
harvested from two healthy donors. Cells were isolated using
a separation gradient (Lymphoprep, Nycomed Pharma AS,
Oslo, Norway) and 1 × 106 MNC were suspended in RPMI-
1640 supplemented medium and 100μL/well placed in 96-
well plates. MNC were treated on the same day as harvesting.
2.5. Cell Proliferation Assay. Adherent cells (HT29, Caco-2,
MCF-7, HeLa and IEC-6) were grown to 70% conﬂuence
then detached from ﬂasks with 1 × Trypsin-EDTA (Gibco)
and resuspended at 1 × 105 cells/mL. Cells were dispensed
into 96-well plates (Nunc, Roskilde, Denmark) at a ﬁnal
concentration of 1 × 104 cells/well and incubated overnight.
Media was removed and replaced prior to treatment. Sus-
pension cell lines (Jurkat and U937) and MNC were washed
once with PBS and suspended at 1 ×105 cells/mL. Cells were
dispensed at a ﬁnal concentration of 1 × 104 cells/well and
incubated overnight before treatment. The eﬀect of the test
samples on cell viability was measured using the MTS cell
proliferation assay, which measures the reduction of MTS
tetrazolium salt to formazan in metabolically active cells
[32].
Due to the poor solubility of crude and semi-puriﬁed
extracts in aqueous solution, extracts were dissolved in 100%
dimethylsulphoxide (DMSO, Sigma, USA) fresh on the
day of testing and added to the cell cultures (in triplicate),
ranging in concentration from 0.01mg/mL to 1mg/mL
(ﬁnal DMSO concentration of 2%). The concentrated Murex
remedy was also dissolved in DMSO and tested at a ﬁnal
concentration 4mg/mL. The diluted Murex remedy was
testedneatbyadding2μLto98μLofcellculture(i.e.,50-fold
dilution). According to the manufacturers recommendations
the Murex remedy (1M) should be diluted before use (four
drops into one teaspoonful H2O), therefore our tests of the
d i l u t e dp r o d u c tp r o v i d ear e l e v a n tt e s to fb i o a c t i v i t yf o r
homeopathic application. Appropriate media and solvent
(2% DMSO for the concentrated extract and 20% EtOH
in water for the dilute Murex) controls were also prepared
in triplicate. All samples were incubated with the cells for4 Evidence-Based Complementary and Alternative Medicine
4hbefore20μL of MTS [3-(4,5-dimthylthiazol-2-yl)-5-(3-
carboymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium,
inner salt] reagent (Promega Co. Madison, WI, USA) was
added to each well. Cells were incubated for a further
1.5h to allow for color development before the absorbance
values were read at 492nm using a Multiscan plate reader
(Labsystems, Virginia, USA) and Accent software 2.6.
Background absorbance from controls involving the test
samples incubated in media with the MTS reagent, were
subtracted from sample wells after the ﬁnal absorbance was
obtained. Repeat assays were conducted on all samples on
at least three separate occasions with independent extracts,
with the exception of the concentrated and dilute Murex
remedy which was tested in quadruplicate and repeated on
two separate occasions.
2.6. Statistical Analysis. A l lt r e a t m e n t( c r u d ee x t r a c t ,s e m i -
puriﬁedandtheMurex remedy)datapointswerenormalized
to the relevant solvent controls and expressed as percentage
cell viability. The data are represented as the average of
triplicate samples and are expressed as the mean ± SE
of repeat experiments. Signiﬁcant diﬀerences in percentage
viability between the diﬀerent treatments concentrations
were tested using one way Analysis of Variance (ANOVA), or
the Kruskal-Wallis test for nonparametric data, on SPSS 14.0
statistical software. P<. 05 was used to establish signiﬁcant
dose eﬀects for each test sample against each cell line.
2.7. Flow Cytometry Analysis. HT29 and Jurkat cells
were cultured in 24-well plates (in duplicate) with 1 ×
105 cells/well, incubated overnight and treated with extracts
the following day as described above. Adherent cells were
detached from the wells using 1x trypsin-EDTA solution
(Gibco), and manual pipetting. Cells were placed in 10mL
tubes before centrifugation at 150rpm for 3min. Media was
removed without disturbing the cells. The pellet was washed
twice with cold sterilized phosphate buﬀered saline (PBS, pH
7.4) and centrifuged. Cells were then suspended in 200μL
of 1x Binding buﬀer (10mM Hepes/NaOH, pH 7.4, 140mM
NaCl and 2.5mM CaCl2). Prior to analysis, propidium
iodide (PI, Sigma) at 10μg/mL ﬁnal concentration and 5μL
Annexin-V-FITC (BD Biosciences, NJ, USA) were added to
each tube. Analyses were performed using FACSan Flow
Cytometer (Becton Dickinson) with the CellQuest program
(Becton Dickinson) and FlowJo 7.2.2 analysis software (Tree
Star Inc.). Compensation was performed with appropriate
solvent controls for each analysis.
3. Results
3.1. Chemical Analysis. LC-MS analysis of chloroform-
soluble extracts from D. orbita egg masses revealed ﬁve peaks
corresponding to brominated indoles (Figure 2). The dom-
inant compound present in the crude extract (Figure 2(a))
registered an HPLC peak at 6.4 min and major ions at m/z
224, 226, that can be attributed to the pseuomolecular ion
[M-H]+ of 6-bromoisatin (Figure 1(f), molecular mass of
225, 227 for Br79,B r 81). Another dominant peak occurred
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Figure 2: LC-MS analysis showing representative chromatograms
from the UV diode array at 300nm; (a) Crude extract from egg
capsules of D. orbita; (b) Semi-puriﬁed fraction from the crude
extract and (c) the Murex remedy. The peaks correspond to bromi-
nated indoles, where b, tyrindoxyl sulphate; c: tyrindoleninone; d:
tyrindolinone; e: tyriverdin; f: 6-bromoisatin. Note that due to the
low detection ofany compounds in the concentrated Murex remedy
sample, the y-axis has an intensity of approximately 10 times less
than the egg extracts.
at 11.3min with major ions in ESI-MS at m/z 255, 257
corresponding to the molecular mass of tyrindoleninone
(Figure 1(c)) and a smaller peak at 9.5min had m/z 303,
305 corresponding to the molecular weight of tyrindolinoneEvidence-Based Complementary and Alternative Medicine 5
[6-bromo-2,2-dimethylthioindolin-3-one] (Figure 1(d)) a
methanethioladductoftyrindoleninone.Anadditionalpeak
at 12.1min registered an isotopic cluster at m/z 513, 515,
517 (in a peak height ratio of 1:2:1) corresponding to
the molecular ion of tyriverdin (MH+;B r 79 Br79,B r 79 Br81,
Br81 Br81). Additional fragment ion triplets (indicating two
bromines still attached) were centered around m/z 465 (Br79
Br81) from the elimination of a single methane thiol group,
and majors peaks at m/z 419 [Br79 Br81 (MH-2SCH3)+]
conﬁrming this peak as tyriverdin (Figure 1(e)). A minor
HPLC peak at 5.1min in the crude extract (Figure 2(a))
correspondstotyrindoxylsulphate(Figure 1(b)),withmajor
ions in ESI-MS at m/z 338, 336.
LC-MS analysis revealed that semi-puriﬁcation of the D.
orbitaeggextract(Figure 2(b))bysilicachromatographywas
successful in concentrating tyrindoleninone (c). The relative
proportion of tyrindoleninone increased from 31.12% of
the crude extract (Figure 2(a)) to 61.72% of the semi-
puriﬁed fraction (Figure 2(b)) based on spectral analysis of
absorption at 300 nm. There was a corresponding decrease
in the relative proportion of 6-bromoisatin (f) from 52.97%
of the crude extract (Figure 2(a)) to 18.88% in the semi-
purefraction(Figure 2(b)).Tyrindolinone(d)andtyriverdin
(e) remained present as minor components in the semi-pure
fraction (Figure 2(b)).
It was diﬃcult to register any compounds from peaks
absorbing in the UV-Vis range from the diode array chro-
matogramoftheconcentratedMurex remedy.However,after
decreasing the y-axis scale to intensify the peaks, two bromi-
nated compounds were detected at 300nm (Figure 2(c)).
At 6.3 min, 6-bromoisatin (f, M+ 225, 227) was detected
representing a relative proportion (59.35%) of the integrated
area from all peaks registering at 300 nm. A co-eluting
peak at 5.4 min was identiﬁed as tyrindoxyl sulphate (b,
M+ = 338, 336), representing approximately 9.1% of the
concentrated Murex remedy extract. None of the other peaks
produced isotopic ion clusters characteristic of brominated
compounds or molecular ions corresponding to indoles as
previously recorded in Muricidae extracts [9, 12, 15].
3.2. Eﬀects on Cell Viability. The DMSO solutions of the
chloroform-soluble crude extract from D. orbita egg masses
were found to reduce the production of formazan relative
to solvent controls in all cell lines at a concentration of
1mg/mL, with additional eﬀects at lower concentrations
with all solid tumor and U937 lymphoma cells (Figure 3(a)).
At the highest concentration of 1mg/mL, a mean reduction
of 39.7% cell viability was observed for the untransformed
IEC-6 cells (Figure 3(a)), compared with a 78.5% mean
reduction in HT29 colorectal carcinoma and 66.7% mean
reduction in Caco-2 colorectal carcinoma cell viability.
Reductions in cell viability also occurred in these solid
tumors incubated with 0.5mg/mL crude extract, which
caused over 70% reduction in formazan production for
HT29 cells and over 40% reduction for Caco-2 and MCF-
7 cells. Further reductions of over 20% cell viability were
observed at 0.01mg/mL for HT29 cells, as well as in MCF-
7 cells incubated with both 0.1mg/mL and 0.01mg/mL
extract. Signiﬁcant dose eﬀects were observed in all solid
tumor cell lines (P<. 05), with lower cell viability recorded
at the higher treatment concentrations (Figure 3).
Semi-puriﬁcation of the D. orbita egg chloroform-
soluble extract was successful in increasing the eﬀects
on cell viability against some of the adherent cell lines
(Figure 3), but in a non-predictable manner. Stronger
activity was observed against the untransformed IEC-6
rat epithelial cells (Figure 3(b)), with signiﬁcantly lower
cell viability at 1mg/mL compared with the other test
concentrations. Greater activity of the semi-puriﬁed extract
was also observed against Caco-2 cells at the lower test
concentrations, with over 60% reduction in cell viability
at 0.1mg/mL (Figure 3(b)). In comparison to the crude
extracts (Figure 3(a)), MCF-7 breast carcinoma cells also
showedgreatermeanreductionincellviability(>50%)when
incubated with 0.1–1mg/mL of the semi-puriﬁed extract
(Figure 3(b)), However, less activity was observed against
the colorectal carcinoma cell line HT29 (Figure 3(b)). No
signiﬁcant dose eﬀects were observed with the semi-puriﬁed
extracts against any of these solid tumors (P>. 05).
Treatment of the T cell lymphomas with the crude
extracts resulted in reductions of over 50% cell viability at
1a n d0 . 5 m g / m L( Figure 3(a)). By comparison, treatment
of normal MNC resulted in only a small reduction in
cell viability at the highest concentration (1mg/mL, 30.8%
reduction). Unlike the adherent cell lines, no signiﬁcant
dose eﬀects were observed for the Jurkat and U937 cells,
but rather, relatively large variation was observed between
repeat assays and replicates (Figure 3(a)). Much stronger
eﬀects on cell viability were found with the semi-puriﬁed
extracts against both the lymphoma cell lines (Figure 3).
For the Jurkat cells, there was a signiﬁcant reduction in cell
proliferation by almost 80% when treated with the semi-
puriﬁed extracts at 1mg/mL. Further eﬀects of the semi-
puriﬁed extracts were observed at the lower concentrations
of 0.01 and 0.1mg/mL, with less than 80% of the cells
remaining viable (Figure 3(b)). In U937 cells, a reduction in
cell viability to around 50% of the solvent control resulted
afterincubationwiththesemi-puriﬁedextractat0.1mg/mL,
compared with over 90% cell viability with the crude
extractatthisconcentration(Figure 3).CellviabilityofU937
cells was signiﬁcantly reduced by treatment with the semi-
puriﬁed extract at 0.1mg/mL compared with 0.01mg/mL
(P = .0001).
No reduction in cell viability was seen in the majority of
cell lines treated with the dilute Murex remedy (Figure 3(c)).
Similarly, no eﬀects were seen with the concentrated Murex
remedy (4mg/mL), with the exception of the histiocytic
lymphoma cell line U937, in which cell viability was reduced
by 35% (Figure 3(c)). Cell viability of U937 cells was
signiﬁcantly lower after treatment with the concentrated
productcomparedwiththediluteremedy(P = .004).Amild
increaseintheamountofformazanproductionwasobserved
in HT29, Caco-2 and MCF-7 cells treated with the dilute
Murex remedy relative to solvent controls (mean > 100%,
Figure 3(c)), although no statistically signiﬁcant diﬀerence
in cell viability was detected relative to the concentrated
treatments.6 Evidence-Based Complementary and Alternative Medicine
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Figure 3: Percent cell viability of a range of solid and haemopoietic cell lines exposed for 4h to varying concentrations of (a) crude
extract; (b) semi-puriﬁed fraction (concentrating the tyrindoleninone compound) from D. orbita and (c) the Murex r e m e d y .C e l lv i a b i l i t y
is determined by the percent absorbance at 490nm relative to solvent controls, based on the conversion of a tetrazolium salt to formazan in
the MTS cell proliferation assay. Cells were treated in triplicate and the assay repeated on separate occasions, shown as mean ± SE of repeat
experiments.
3.3. Initiation of Necrosis and Apoptosis. Flow cytometric
analysis revealed that Jurkat cells treated with 1 mg/mL
DMSO solution of chloroform-soluble crude extract for
4h(Figure 4(d)) underwent an induction of both necrosis
(54.89% PI positive) and apoptosis (44.95% Annexin-V pos-
itive) compared with the treatment control (11% Annexin-V
positive, 8.07% PI positive, Figure 4(a)). In contrast, HT29
cells treated with the DMSO solution of chloroform-soluble
crude extract were predominantly PI positive (Figures
5(b)–5(d)), indicating that they were undergoing necrosis.
At 1mg/mL, over 80% of HT29 cells were PI positive
(Figure 5(d)), compared with 11.68% of the solvent control
cells (Figure 5(a)). An increase in the proportion of PI
positive cells was also observed in HT29 cells treated with 0.5
(Figure 5(c))a n d0 . 1 m g / m L( Figure 5(b)) compared with
the solvent control (Figures 5(a) and 6(b)), whereas an
increase in PI positive Jurkat cells was only observed at the
highest concentration of 1mg/mL (Figure 6(a)). On average,
almost double the amount of Jurkat cells were Annexin-
V positive at the lower concentration of 0.5mg/mL, when
compared with the solvent control (Figure 6(a)), whereas no
obvious increases the proportion of Annexin-V positive cells
was observed for HT29 cells treated at any concentration of
the egg extract (Figure 6(b)).
4. Discussion
This study conﬁrms the presence of brominated indoles with
anticancer activity in extracts from the egg masses of the
Australian mollusc D. orbita. Despite the detection of trace
amounts of two brominated indoles in the commercially
availableMurex remedy,nosigniﬁcanteﬀectsoncellviability
were observed with extracts of this commercial product in
a wide range of cell lines, with the exception of a mild
reduction in the histiocytic lymphoma cell line U937 after
treatment with the concentrated product. Consequently, the
anticancer applications of this natural remedy cannot be
substantiated byour study.Nevertheless,thebroadspectrum
reduction in cell viability in solid tumor and lymphomaEvidence-Based Complementary and Alternative Medicine 7
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Figure 4:RepresentativeﬂowcytometricanalysisofJurkatTcelllymphomacells(1 ×105)treatedwith;(a)DMSOonly(ﬁnalconcentration
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Annexin-V positive cells, FL2 (y-axis) shows propidium iodide (PI) positive cells. Cells were treated in duplicate, dual stained with PI and
Annexin-V-FITC and analyzed using a FACscan ﬂow cytometer and FlowJo analysis software.
cell lines treated with our crude and semi-puriﬁed egg
extracts imply that there is potential for optimizing a natural
anticancer remedy from the Muricidae. The crude extract
was found to have diﬀerential eﬀects depending on cell
phenotype, inducing both apoptosis and necrosis in Jurkat
cell lines, whereas strongly necrotic eﬀects were observed
with HT29 carcinoma cells.
Anti-proliferative eﬀects in the crude extract obtained
from the egg masses of D. orbita were predominantly seen
in the cancer derived cell lines, with less activity towards the
untransformed rat small intestine epithelial cell line IEC-6
and the freshly isolated MNC. This dose dependant speci-
ﬁcity towards transformed cancer cell lines is useful because
non-speciﬁc cytotoxicity towards healthy cells is a major8 Evidence-Based Complementary and Alternative Medicine
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Figure 5: Representative ﬂow cytometric analysis of HT29 colorectal carcinoma cells (1 × 105) treated with; (a) DMSO only (ﬁnal
concentration 2%); (b) 0.1 mg/mL of crude extract; (c) 0.5mg/mL of crude extract and (d) 1mg/mL crude extract from D. orbita for 4
h. FL1 (x-axis) shows Annexin-V positive cells, FL2 (y-axis) shows propidium iodide (PI) positive cells. Cells were treated in duplicate, dual
stained with PI and Annexin-V-FITC and analyzed using a FACscan ﬂow cytometer and FlowJo analysis software.
limitation in the development of many marine natural prod-
ucts as anticancer agents [4, 33]. Semi-puriﬁcation of the egg
extractwassuccessfulinincreasingtherelativeconcentration
of tyrindoleninone relative to that of 6-bromoisatin. How-
ever, this resulted in increased activity towards benign gut
epithelial cells and did not consistently increase the potency
towards all the solid tumor cell lines tested. This indicates
that some cell lines (e.g., HT29) are relatively resilient to
the anti-proliferation eﬀects of tyrindoleninone, compared
with the known cytotoxic eﬀects of 6-bromoisatin [11, 14],
whereas other cell lines (e.g., IEC-6 and the lymphoma
cells) are more susceptible to higher concentrations of
tyrindoleninone. These observed diﬀerences in cell line
speciﬁcity may indicate the bioactive compounds within
the extracts target alternative pathways depending on cell
phenotype, as suggested by Nguyen and Wells [34].
Our results indicate that there is potential for optimizing
the composition and delivery of Muricidae extracts for the
treatment of diﬀerent cancers by concentrating the diﬀerent
brominated indoles. The strongest eﬀects on cell viabilityEvidence-Based Complementary and Alternative Medicine 9
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Figure 6: Mean (±SE) proportion of gated cell populations from
repeatﬂowcytometryexperimentsfor(a)Jurkat(Tcelllymphoma)
cells and (b) HT29 (colorectal carcinoma) cells demonstrating the
percentage of cells positive for PI and Annexin-V.
using the crude D. orbita extract were exerted against the
HT29 colon carcinoma cells. This is in contrast to previous
studies on the anticancer eﬀects of indole derivatives, where
Vine et al. [14]r e p o r t e dg r e a t e re ﬀects on lymphoma cells
compared with solid tumors in a range of synthetic isatin
derivatives and Hoessel et al. [22] found HT29 cells to be
insensitive to indirubin-3 -monoxime. The relatively strong
selective inhibition observed towards colon carcinomas
treated with the D. orbita crude extract is of particular
interest considering that D. orbita is an edible species of
marine mollusc. The bioactive brominated indoles found in
the chloroform-soluble egg extracts are also present in the
hypobranchial and reproductive organs of adult D. orbita
[15] and appear to be retained after boiling the snails (KB,
unpublished data). The Muricidae are heavily ﬁshed as a
source of protein in many countries around the world [35]
suggesting potential for development as a medicinal food.
In some cultures (e.g., Asia), Muricidae are often consumed
whole, with the hypobranchial gland intact (KB, personal
observation), whereas in other cases (e.g., Mediterranean)
the hypobranchial gland is typically discarded along with
the visceral organs. Our tasting of the hypobranchial glands
from D. orbita indicates that it is bitter and leaves a numbing
eﬀect on the mouth, most likely due to the muscle relaxing
choline esters which are also produced in this organ [10,
36]. Further studies are required to establish whether the
bioactive compounds from Muricidae are nontoxic and
bioavailable after digestion.
In contrast to the HT29 carcinomas, greater activity was
observed against the U937 and Jurkat lymphoma cells using
the semi-puriﬁed extract. Nevertheless, the level of activity
observed was somewhat disappointing based on a previous
study [11], where D. orbita egg extracts were reported to
cause over 80% reduction in the cell viability of U937 cells
after 1h incubation at 0.01mg/mL. Furthermore, the level
of activity observed in the semi-puriﬁed extract is nowhere
in the order of the LC50 of 4μM predicted by Vine et al.
[14] for tyrindoleninone. These diﬀerences could be due to
variability in growth parameters of diﬀerent cultures of the
samecellline[37,38]orvariabilityinproportionofbioactive
compounds present in the extracts from the egg masses. It is
also possible that the contaminating plasticizer in the previ-
o u ss t u d i e s[ 14] acted synergistically with tyrindoleninone
by increasing its solubility and or stability in the media.
This would increase its bioavailability to the cells at low
concentrations, in comparison to the strongly lipophylic
nature of our extracts, which could lead to micelle formation
in the aqueous media. Attempts by Vine et al. [14]h a v e
failed to synthesize tyrindoleninone in the laboratory, due to
instability of theprecursors with O2 exposure. Consequently,
it will be diﬃcult to establish the true eﬀective lethal dose or
minimum inhibitory concentration of this biologically active
marine natural product.
ThediﬀerentialactivityofD.orbitaextractstowardssolid
tumors and suspension cells could have useful implications
for understanding the mode of action and in particu-
lar, whether the bioactive compounds eﬀectively induce
programmed cell death. Nguyen and Wells [34]f o u n d
that apoptosis was not induced in all cell lines while
investigating compound eﬀects on cytochrome c-induced
caspase activation and attributed this to the possibility that
diﬀerential expression of various pro- and anti-apoptotic
factors may provide a strategy for selectivity. An interesting
ﬁnding from our ﬂow cytometry analyses was the increase
in apoptosis in Jurkat cells treated with all concentrations
of the extracts relative to the solvent controls. However,
HT29 treated cells predominantly underwent necrosis with
little increase in Annexin-V positivity. This is consistent
with previous reports that apoptosis is characteristic for
lymphoid cells, but is an insigniﬁcant mode of cell death for
many solid tumors [39]. The necrotic eﬀects are most likely
attributed to 6-bromoisatin, the dominant compound in
the chloroform-soluble crude extract (Figure 7), as previous
studies have indicated the cytotoxic behavior of brominated
isatin derivatives at concentrations greater than 10μg/mL10 Evidence-Based Complementary and Alternative Medicine
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Figure 7: Chloroform extracts from D. orbita egg masses contain at least two brominated indoles with anti-cancer activity that can be
puriﬁed by silica chromotography. The orange fraction contains tyrindoleninone, which is predicted to induce apoptosis in lymphoma cells,
whereas the more polar yellow compound is the cytotoxin 6-bromoisatin, which causes necrosis in lymphoma and solid tumor cell lines.
[14].ItisunclearwhyJurkatcellsappeartobelesssusceptible
to these cytotoxic eﬀects, although semi-puriﬁcation of
the extracts to reduce bromoisatin relative to tyrindoleni-
none could reduce the necrotic eﬀects on both cells lines
(Figure 7). Further investigation into the mode of action
of our semi-puriﬁed extracts and/or the isolated bioactive
secondary metabolites is warranted, to determine which
cellular pathways are targeted by these compounds.
Using LC-MS analysis we identiﬁed the presence of 6-
bromoisatin and trace amounts of tyrindoxyl sulphate in
the Murex remedy. The presence of tyrindoxyl sulphate
conﬁrms the Murex remedy as originating from the hypo-
branchial glands of Muricidae, as this compound was ﬁrst
reported from D. orbita [40] and has only subsequently
been reported from other species in the same family of
molluscs [9]. However, despite the fact that this secretion
is sourced from the “purple secretion”, the Tyrian Purple
pigments 6,6 -dibromoindigotin and its biologically active
structural isomer 6,6 -dibromoindirubin, were not detected.
This is possibly due to the insolubility of these hydrophobic
compounds in 20% aqueous ethanol, which is the delivery
agent used in the homeopathic product. The presence of 6-
bromoisatin implies that at least some tyrindoxyl sulphate
has undergone enzymatic cleavage or acid hydrolysis and
oxidation to enable formation of the end products [9].
But despite the presence of 6-bromoisatin, we observed no
signiﬁcant reduction of cell viability in any of the solid
tumorsandonlyaslightreductioninonelymphomacellline
tested using the concentrated Murex remedy. Consequently,
6-bromoisatin must not be present in suﬃcient quantities in
the Murex remedy to exert a strong eﬀect, possibly due to
dilution with other compounds that could not be detected
in the LC-MS. Previous chemical studies on homeopathic
solutions have indicated that the results often cannot be
reproduced [41]. Similarly, our LC-MS on diﬀerent batches
of the Murex remedy indicated variability in the detection
of 6-bromoisatin (data not shown), although all of our
assays were performed on a batch containing the maximum
concentration of this compound as shown in Figure 2(c).
Homeopathic practitioners frequently prescribe medicines
in extremely high dilutions, including dilutions whereby
not a single molecule of the starting substance is present
(“ultramolecular” dilutions) [42]. Therefore, in many cases
anecdotal reports of the beneﬁts of homeopathic treatment
may be attributed to the placebo eﬀect. Homeopathy is
drawn from the central principle of treating like with like
[42]andnotably,therewasaslight(non-signiﬁcant)increase
inthecellproliferationofsolidtumorstreatedwiththedilute
remedy. Nevertheless, these eﬀects were not increased in the
c o n c e n t r a t e dp r o d u c t ,a sw o u l db ee x p e c t e df o ram i l dp r o -
moter of cell replication. Consequently, our results suggest
that the use of the Murex remedy remains unsubstantiated as
a natural homeopathic remedy for the treatment of cancer.
Given that the main application of the Murex remedy is
for Women’s problems, our ongoing research will continue
to explore the eﬀects on cell proliferation and hormone
production in uterine cancer and granulosa cells.
Here we have identiﬁed bioactive brominated indoles in
the commercially available Murex remedy and extracts from
the fresh egg capsules of the Australian muricid D. orbita.
Concentration of the Murex remedy did not signiﬁcantly
reduce cell viability in a metabolic cell proliferation assay,
in most of the cell lines tested. In contrast, both crude and
semi-puriﬁed extracts signiﬁcantly reduced proliferation in a
range of solid tumor and lymphoma cell lines. The strongest
anti-proliferative activity in the crude extract was observed
against HT29 colon carcinomas and ﬂow cytometry revealed
signiﬁcantly increased necrosis compared with treatment
controls after only 4h. The crude extract was found to
induceapoptosisandnecrosisinJurkatTcelllymphomacells
(Figure 7)andsemi-puriﬁcationoftheextracttoconcentrate
tyrindoleninone resulted in increased eﬀects on the cell
viability of both lymphoma cell lines tested in the MTS assay.
These results indicate the potential to optimize bioactive
muricidextractsfordevelopmentasalternativemedicinesfor
the treatment of cancer.Evidence-Based Complementary and Alternative Medicine 11
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